Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.89)
# 1,517
Out of 5,138 analysts
45
Total ratings
41.18%
Success rate
57.56%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NXTC NextCure | Upgrades: Buy | $18 | $13.45 | +33.83% | 1 | Nov 7, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $11.62 | +29.09% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $2.81 | +576.16% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $13.02 | +130.50% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.18 | +1,764.41% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $9.39 | +155.59% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $27.69 | +351.51% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $3.58 | +402.79% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $3.50 | +442.86% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $2.38 | - | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $184.06 | -56.99% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $102.35 | +51.44% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $9.61 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $2.89 | +765.05% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $4.68 | +38,361.54% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $36.29 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.64 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.64 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $3.50 | +42,757.14% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.44 | +62,400.00% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $8.20 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $14.00 | +1,078.57% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $5.68 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.61 | - | 2 | Jan 4, 2017 |
NextCure
Nov 7, 2025
Upgrades: Buy
Price Target: $18
Current: $13.45
Upside: +33.83%
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $11.62
Upside: +29.09%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $2.81
Upside: +576.16%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $13.02
Upside: +130.50%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.18
Upside: +1,764.41%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $9.39
Upside: +155.59%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $27.69
Upside: +351.51%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $3.58
Upside: +402.79%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.50
Upside: +442.86%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.38
Upside: -
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $184.06
Upside: -56.99%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $102.35
Upside: +51.44%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $9.61
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $2.89
Upside: +765.05%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $4.68
Upside: +38,361.54%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $36.29
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.64
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.64
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $3.50
Upside: +42,757.14%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.44
Upside: +62,400.00%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $8.20
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $14.00
Upside: +1,078.57%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $5.68
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $1.61
Upside: -